PRTA

About PRTA

Prothena Corporation Public Limited Company is a late-stage clinical company engaged in the protein dysregulation and a pipeline of investigational therapies for rare peripheral amyloid and neurodegenerative diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The Company's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.